Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $17.93.

A number of brokerages have weighed in on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, Bank of America upped their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th.

Insider Transactions at Roivant Sciences

In related news, CIO Mayukh Sukhatme sold 185,946 shares of Roivant Sciences stock in a transaction on Tuesday, December 24th. The shares were sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,038,564. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the transaction, the chief operating officer now owns 617,470 shares in the company, valued at $7,193,525.50. This represents a 13.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,071,486 over the last quarter. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. JPMorgan Chase & Co. grew its position in shares of Roivant Sciences by 4.4% during the third quarter. JPMorgan Chase & Co. now owns 822,582 shares of the company’s stock worth $9,493,000 after buying an additional 34,453 shares in the last quarter. Retirement Systems of Alabama boosted its stake in Roivant Sciences by 26.9% during the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the last quarter. Tyro Capital Management LLC grew its holdings in Roivant Sciences by 0.6% during the 3rd quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock worth $20,252,000 after acquiring an additional 10,649 shares in the last quarter. Te Ahumairangi Investment Management Ltd increased its position in shares of Roivant Sciences by 19.9% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company’s stock worth $2,313,000 after purchasing an additional 33,467 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $207,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

ROIV opened at $12.08 on Friday. Roivant Sciences has a 1 year low of $9.69 and a 1 year high of $13.06. The company’s 50 day simple moving average is $11.92 and its 200 day simple moving average is $11.56. The stock has a market capitalization of $8.79 billion, a PE ratio of 2.14 and a beta of 1.25.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.